Cargando…

Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries

OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a determini...

Descripción completa

Detalles Bibliográficos
Autores principales: Marseille, Elliot, Jiwani, Aliya, Raut, Abhishek, Verguet, Stéphane, Walson, Judd, Kahn, James G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078786/
https://www.ncbi.nlm.nih.gov/pubmed/24969782
http://dx.doi.org/10.1136/bmjopen-2013-003987
_version_ 1782323795952926720
author Marseille, Elliot
Jiwani, Aliya
Raut, Abhishek
Verguet, Stéphane
Walson, Judd
Kahn, James G
author_facet Marseille, Elliot
Jiwani, Aliya
Raut, Abhishek
Verguet, Stéphane
Walson, Judd
Kahn, James G
author_sort Marseille, Elliot
collection PubMed
description OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.
format Online
Article
Text
id pubmed-4078786
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-40787862014-07-03 Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries Marseille, Elliot Jiwani, Aliya Raut, Abhishek Verguet, Stéphane Walson, Judd Kahn, James G BMJ Open Global Health OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health. BMJ Publishing Group 2014-06-26 /pmc/articles/PMC4078786/ /pubmed/24969782 http://dx.doi.org/10.1136/bmjopen-2013-003987 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Global Health
Marseille, Elliot
Jiwani, Aliya
Raut, Abhishek
Verguet, Stéphane
Walson, Judd
Kahn, James G
Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries
title Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries
title_full Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries
title_fullStr Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries
title_full_unstemmed Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries
title_short Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries
title_sort scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries
topic Global Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078786/
https://www.ncbi.nlm.nih.gov/pubmed/24969782
http://dx.doi.org/10.1136/bmjopen-2013-003987
work_keys_str_mv AT marseilleelliot scalingupintegratedpreventioncampaignsforglobalhealthcostsandcosteffectivenessin70countries
AT jiwanialiya scalingupintegratedpreventioncampaignsforglobalhealthcostsandcosteffectivenessin70countries
AT rautabhishek scalingupintegratedpreventioncampaignsforglobalhealthcostsandcosteffectivenessin70countries
AT verguetstephane scalingupintegratedpreventioncampaignsforglobalhealthcostsandcosteffectivenessin70countries
AT walsonjudd scalingupintegratedpreventioncampaignsforglobalhealthcostsandcosteffectivenessin70countries
AT kahnjamesg scalingupintegratedpreventioncampaignsforglobalhealthcostsandcosteffectivenessin70countries